Per Petersen has been appointed to Invitrogen’s board of directors after retiring from his post at the chairman of R&D at Johnson & Johnson, the company said last week.
At J&J, Peterson was responsible for the Office of Science and Technology, the R&D Council, and the cell therapy research and activities. Prior to that, Peterson was chairman of the Department of Immunology at the Scripps Research Institute.
Hoefer Scientific Instruments has appointed Mark Daniels to be a consultant and manager for the company’s distribution network in Asia, the company said last week.
Daniels formerly supported Hoefer products in Asia with Pharmacia Biotech, Amersham Biosciences, and GE Healthcare.
Nanogen this week reported it has signed a new contract with chairman and CEO Howard Birndorf for a three-year, $520,000 deal that offers potential bonuses that may be as much as 80 percent of his base salary.
The company also has signed new contracts with officers David Ludvigson, William Respess, Robert Saltmarsh, and Graham Lidgard: Ludvigson will receive a base salary of $360,000 with a $180,000 bonus potential; Lidgard will receive $290,000 with a $116,000 bonus potential; Respass will receive $329,000 with a $130,000 bonus potential; and Saltmarsh will receive $257,000 with a $103,000 bonus potential.